The small molecule drug developer, co-founded by a UCLA associate professor, has completed its series B round.
Octant Bio, a US-based small molecule therapeutics developer co-founded by Sri Kosuri, an associate professor at University of California, Los Angeles (UCLA), has secured $80m in its series B round. Life sciences investment firm Catalio Capital Management led the round, which also featured pharmaceutical firm Bristol Myers Squibb (BMS), boutique investment bank Allen & Company and…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
